Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 10, 2014, Pages 1077-1100

  Shanthi, Ekambaram ^a   Krishna, Mudeenahally H ^a   Arunesh, Gubbi M ^a   Venkateswara Reddy, K ^a   Sooriya Kumar, Jegatheesan ^a   Viswanadhan, Vellarkad N ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

apoptosis; cancer; clinical trial; expression; focal adhesion kinase; growth; inhibitor; metastasis; migration; proliferation; signaling; survival

Indexed keywords

FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; BREAST CANCER; CELL MIGRATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); NEOPLASMS; PHYSIOLOGY;

CLINICAL TRIALS AS TOPIC; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84907258755     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.948845     Document Type: Review

References (151)

1. Kanner SB, Reynolds AB, Vines RR, et al. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci USA 1990; 87: 3328-32
2. Schaller MD, Borgman CA, Cobb B. S, et al. pp125FAK, A structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89: 5192-6
3. Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 1992; 358: 690-2
4. Guan JL, Trevithick JE, Hynes RO. Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein. Cell Regul 1991; 2: 951-64
5. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005; 6: 56-68
6. Troyanovsky SM. Mechanism of cell-cell adhesion complex assembly. Curr Opin Cell Biol 1999; 11: 561-6
7. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009; 28: 35-49
8. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011; 63: 610-15
9. Whitney GS, Chan PY, Blake J, et al. Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK. DNA Cell Biol 1993; 12: 823-30
10. Liu G, Guibao CD, Zheng J. Structural insight into the mechanisms of targeting and signaling of focal adhesion kinase. Mol Cell Biol 2002; 22: 2751-60
11. Lietha D, Cai X, Ceccarelli DF. Structural basis for the autoinhibition of focal adhesion kinase. Cell 2007; 129: 1177-87
12. Thomas JW, Cooley MA, Broome JM, et al. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem 1999; 274: 36684-92
13. Eleniste PP, Bruzzaniti A. Focal adhesion kinases in adhesion structures and disease. J Signal Transduct 2012; 2012: 296450
14. The interaction of Src SH2 with the focal adhesion kinase catalytic domain studied by NMR. Available from: https://openaccess.leidenuniv.nl/bitstream/handle/1887/14593/06.pdf?sequence=11
15. Tomita N, Hayashi Y, Suzuki S, et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett 2013; 23: 1779-85
16. Han S, Mistry A, Chang JS, et al. Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design. J Biol Chem 2009; 284: 13193-201
17. Cary LA, Guan JL. Focal adhesion kinase in integrin-mediated signaling. Front Biosci 1999; 4: D102-13
18. Lal H, Verma SK, Foster DM, et al. Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci 2009; 14: 2307-34
19. Cance W. Focal adhesion kinase-tumor biology and therapeutics. Available from: http://center.ncet2.org/index.php?option=com-patents&controller=awards&tmpl=component&view=awards&layout=award&frame=awards&user=83557&id=6085
20. Guan JL. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol 1997; 29: 1085-96
21. Klemke RL, Leng J, Molander R, et al. Cas/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998; 140: 961-72
22. Owen JD, Ruest PJ, Fry DW, et al. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto-and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 1999; 19: 4806-18
23. Schlaepfer DD, Hanks SK, Hunter T, et al. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994; 372: 786-91
24. Cohen LA, Guan JL. Mechanisms of focal adhesion kinase regulation. Curr Cancer Drug Targets 2005; 5: 629-43
25. Pandey AK, Somvanshi S, Singh VP. Focal adhesion kinase: an old protein with new roles. OnLine J Bio Sci 2012; 12: 11-14
26. Lim ST, Chen XL, Lim Y, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008; 29: 9-22
27. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24
28. Polte TR, Naftilan AJ, Hanks SK. Focal adhesion kinase is abundant in developing blood vessels and elevation of its phosphotyrosine content in vascular smooth muscle cells is a rapid response to angiotensin II. J Cell Biochem 1994; 55: 106-19
29. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71
30. Eliceiri BP, Cheresh DA. The role of alpha v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-30
31. Eliceiri BP, Puente XS, Hood JD, et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v) beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002; 157: 149-60
32. Sakurama K, Noma K, Takaoka M, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8: 127-34
33. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013; 2: e40
34. Rasool N, LaRochelle W, Zhong H, et al. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res 2010; 16: 600-9
35. Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 2013; 105: 1485-95
36. Annunziata CM, Kohn EC. Novel facts about FAK: new connections to drug resistance? J Natl Cancer Inst 2013; 105: 1430-1
37. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007-13
38. Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 2010; 10: 735-41
39. Jemal A, Siegel R, Ward EM. Cancer facts and figures 2010. American Cancer Society, Atlanta, Georgia. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
40. Golubovskaya VM, Finch R, Kweh F, et al. p53 regulates FAK expression in human tumor cells. Mol Carcinog 2008; 47: 373-82
41. Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal 2008; 1: pe22
42. Lahlou H, Sanguin-Gendreau V, Zuo D, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007; 104: 20302-7
43. Yu HG, Schrader H, Otte JM, et al. Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells. Biochem Pharmacol 2004; 67: 135-46
44. Yu HG, Tong SL, Ding YM, et al. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase. Int J Cancer 2006; 119: 2724-32
45. Li LH, Zheng MH, Luo Q, et al. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol 2010; 37: 951-62
46. Eke I, Deuse Y, Hehlgans S, et al. β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 2012; 122: 1529-40
47. Canel M, Secades P, Garzon-Arango M, et al. Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer 2008; 98: 1274-84
48. Kodama K, Ishii G, Miyamoto S, et al. Laminin 5 expression protects against anoikis at aerogenous spread and lepidic growth of human lung adenocarcinoma. Int J Cancer 2005; 116: 876-84
49. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8: 620-7
50. Wang X, Urvalek AM, Liu J, et al. Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem 2008; 283: 13934-42
51. Gabriel B, Mildenberger S, Weisser CW, et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004; 24: 921-7
52. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67: 10976-83
53. Liu W, Bloom DA, Cance WG, et al. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29: 1096-107
54. Hochwald SN, Nyberg C, Zheng M, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8: 2435-43
55. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: Structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114: 17-22
56. Slack-Davis JK, Adams RB, Rovin JD, et al. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001; 20: 1152-63
57. Slack-Davis JK, Hershey ED, Theodorescu D, et al. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Ther 2009; 8: 2470-7
58. Cance WG, Kurenova E, Marlowe T, et al. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal 2013; 6: pe10
59. Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci 2014; 19: 687-706
60. Goldman E. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Y15 Decreased Glioblastoma Tumor Growth and Increased Lung and Colon Cancer Cell Death. Available from: http://www.prnewswire.com/news-releases/curefaktor-pharmaceuticals-demonstrates-novel-focal-adhesion-kinase-fak-inhibitor-y15-decreased-glioblastoma-tumor-growth-increased-lung-colon-cancer-cell-death-133799418.html
61. FAK Inhibitor 14. A potent FAK inhibitor which demonstrates antiproliferative activity in several tumor cell lines. Available from: http://www.scbt.com/datasheet-203950-fak-inhibitor-14.html
62. Kurenova E, Sanghera S, Liao J, et al. Demonstration of the efficacy of compound CFAK-C4, targeting FAK-VEGFR-3 protein-protein interaction in animal models of gastric cancer. Mol Cancer Ther 2013; 12: C211
63. Liu B, Kurenova E, Cance WG, et al. Physiologically based pharmacokinetic model of CFAK-C4 disposition in mice for understanding its anti-tumor efficacy. Cancer Res 2012; 72 (Suppl 1). doi:10.1158/1538-7445.AM2012-3786
64. Kurenova EV, Sanghera SS, Liao J, et al. Demonstration of the efficacy of compound CFAK-C4 targeting FAK-VEGFR3 protein-protein interaction in gastric cancer. Available from: http://meetinglibrary.asco.org/content/117092-132
65. Golubovskaya VM, Figel S, Ho BT, et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 2012; 33: 1004-13
66. Golubovskaya VM, Nyberg C, Zheng M, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51: 7405-16
67. Buckbinder L, Crawford DT, Qi H, et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci USA 2007; 104: 10619-24
68. Yoon H, Choi Y, Song J, et al. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One 2014; 9 (2): e88587
69. Slack-Davis JK, Martin KH, Tilghman RW, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282: 14845-52
70. Kawahara E, Ohmori O, Nonomura K. NVP-TAE226, a potent dual FAK/IGF-IR kinase inhibitor, prevents breast cancer metastasis in vivo [abstract]. J Clin Oncol 2006; 24 (Suppl): 13163
71. Lietha D, Eck MJ. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 2008; 3: e3800
72. Tong W. Cancer Therapeutics First product achieves preclinical proof of concept. Available from: http://www.businesswire.com/news/home/20120403005748/en/Cancer-Therapeutics%E2%80%99-Product-Achieves-Preclinical-Proof-Concept#.Uxhjeo7rawk
73. Doherty J, Natoli A, Schreuders J. The highly selective focal adhesion kinase inhibitor CTx-0294945 reduces tumour cell growth in an experimental metastasis model. Available from: http://metastasis-2012.p.asnevents.com.au/event/abstract/1279
74. Tong W. CRT to license CTxs FAK inhibitor programmes bringing treatment hope for triple-negative breast cancer. Available from: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/crt-to-license-ctx%E2%80%99s-fak-inhibitor-programmes-bringing-treatment-hope-for-triple-negative-breast
75. Street I, de Sylva M, Lackovic K, et al. Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer. Cancer Res 2012; 72: 8 Suppl. doi:10.1158/1538-7445.AM2012-LB-308
76. Tong W. Cancer Therapeutics reports potent anti-tumour response of CTx-294886. Available from: http://www.drugdevelopment-technology.com/news/newscancer-therapeutics-anti-tumour-response-of-ctx-294886
77. Available from: http://webcache.googleusercontent.com/search?q=cache:cseU9GU-IE4J:www.dynxp.com/discovery/9-dynamix/pipeline/61-fakpyk2+&cd=1&hl=en&ct=clnk&gl=in
78. Infante JR, Camidge DR, Mileshkin LR, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 2012; 30: 1527-33. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=1904753&highlight=
79. Weinberg R. Verastem buys cancer stem cell inhibitor, VS-4718 rights from Poniard pharma. 2014. Available from: http://www.pharmabiz.com/PrintArticle.aspx?aid=80627&sid=2
80. Soria J. Mesothelioma drug slows disease progression in patients with an inactive NF2 gene. Available from: http://www.ecco-org.eu/Global/News/ENA-2012-PR/2012/11/9-11-Mesothelioma-drug-slows-disease-progression.aspx
81. Hirt UA, Braunger J, Schleicher M, et al. Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer. Mol Cancer Ther 2011; 10: Suppl 1. doi:10.1158/1535-7163.TARG-11-A249
82. Jonge MD, Sahebjam S, Mathijssen RH, et al. A phase I, dose-finding study of BI 853520, a potent and selective inhibitor of protein tyrosine kinase 2 in patients with advanced or metastatic solid tumors. Eur J Cancer 2012; 48 (Suppl 6): 120-1
83. Baumgartner R, Wagner F, Doblhofer R. Preclinical and clinical development of 4SC-203, a novel multi-target kinase inhibitor. Available from: http://www.4sc.de/sites/default/files/documents/4SC-203-Poster-ECCO-Stockholm-2011.pdf
84. Aventis Pharma S.A. 7-Substituted aza-indazoles, compositions containing same, production method and use thereof. US20080182844; 2008
85. Aventis Pharma S.A. Organophosphorus derivatives of indazoles and use thereof as medicinal products. US20097491710; 2009
86. Aventis Pharma S.A. Substituted indoles, compositions containing them, method for the production thereof and their use. US20070259910; 2007
87. Aventis Pharma S.A. Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof. US20080139606; 2008
88. Aventis Pharma S.A. Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof. US20080045542; 2008
89. Aventis Pharma S.A. Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation. WO2006077319; 2006
90. Aventis Pharma S.A. Substituted indazoles, compositions containing them, method of production and use. US20056858638; 2005
91. Aventis Pharma S.A. Substituted pyrroles, compositions containing same, method for making same and use thereof. US20080167368; 2008
92. Pfizer Prod, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth. WO2005111016; 2005
93. Pfizer Prod, Inc. Pyrimidines derivatives for the treatment of abnormal cell growth. WO2005111022; 2005
94. Pfizer Prod, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth. WO2005111024; 2005
95. Pfizer Prod, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth. WO2005111023; 2005
96. Pfizer Prod, Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth. US20090054395; 2009
97. Novartis Ag, Novartis Pharma Gmbh. Pyrimidine derivatives. WO2006021454; 2006
98. Novartis Ag, Novartis Pharma Gmbh. 2, 4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. WO2005016894; 2005
99. Novartis Ag, Novartis Pharma Gmbh. Pyrimidine derivatives. WO2003078404; 2003
100. Novartis Ag, Novartis Pharma Gmbh. Pyrimidine derivatives. WO2006021457; 2006
101. Boehringer Ingelheim International Gmbh. 2,4-Diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth. US20138377943; 2013
102. Boehringer Ingelheim International Gmbh. Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors. EP20122483249; 2012
103. Boehringer Ingelheim International Gmbh. 2-Amino-5-trifluoromethyl-pyrimidine derivatives and their use as PTK2 kinase. WO2010058030; 2010
104. Cancer Therapeutics CRC Pty Ltd. Selective fak inhibitors. US20130022594; 2013
105. Cancer Therapeutics CRC Pty Ltd. Selective fak inhibitors. US20130324546; 2013
106. Cancer Therapeutics CRC Pty Ltd. Fak inhibitors. US20130324532; 2013
107. Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor. WO2013134353; 2013
108. Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors. WO2012125603; 2012
109. Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5-a] pyridine derivatives. US20100311693; 2010
110. Korea Institute of Science and Technology. 2,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors. US20120277424; 2012
111. Korea Institute of Science and Technology. 2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors. US20130012703; 2013
112. Korea Institute of Science and Technology. Pyrazole compounds with inhibitory activity against ros kinase. US20110015395A1; 2011
113. OSI Pharmaceuticals, LLC. Macrocyclic kinase inhibitors. US20130261086; 2013
114. OSI Pharmaceuticals, LLC. Amino pyrimidine anticancer compounds. WO2010141406; 2010
115. OSI Pharmaceuticals, LLC. Bicyclic protein kinase inhibitors. US20070149521; 2007
116. Glaxosmithkline, LLC. Pyrazolylaminopyridines as inhibitors of Fak. EP20122421537; 2012
117. Glaxosmithkline, LLC. Benzimidazolecarboxamides as inhibitors of fak. WO2010126922; 2010
118. Abbott Laboratories Trading (Shanghai) Co., Ltd. Benzodiazepinones as fak inhibitors for treatment of cancer. WO2012045194; 2012
119. Abbott Laboratories Trading (Shanghai) Co., Ltd. Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases. WO2012045195; 2012
120. AstraZeneca Ab, AstraZeneca UK Ltd. Pyridine compounds. WO2009153589; 2009
121. AstraZeneca Ab, AstraZeneca UK Ltd. 2,4,Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents. WO2001064656; 2001
122. Bristol-Myers Squibb Co. Novel tyrosine kinase inhibitors. WO2004030620; 2004
123. Bristol-Myers Squibb Co. Novel tyrosine kinase inhibitors. WO2004063151; 2004
124. Poniard Pharmaceuticals, Inc. Method of promoting apoptosis and inhibiting metastasis. US20120196858; 2012
125. Roswell Park Cancer Institute. Kinase protein binding inhibitors. WO2013074517; 2013 Merck
126. Patent Gesellschaft Mit Beschrankter Haftung. Pyrimidine derivatives as fak inhibitors. US20130158005; 2013
127. Centaurus Biopharma Co., Ltd. 2,4-Diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine derivatives as Fak/Pyk2 inhibitors. EP20132661437; 2013
128. The Royal Institute for the Advancement of Learning/McGill University, Ocean University of China. Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof. WO2013059927; 2013
129. Hoffmann La Roche. Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer. WO2009024332; 2009
130. Scripps Research Institute. Inhibitors of focal adhesion kinase. WO2008115369; 2008
131. Agouron Pharma. Diaminothiazoles and their use for inhibiting protein kinases. WO2000075120; 2000
132. Ktb Tumorforschungs Gmbh. Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors. WO2009047216; 2009
133. Smithkline Beecham Corp. Anilinopyridines as inhibitors of fak. WO2009105498; 2009
134. Genosco, Oscotec, Inc. Kinase inhibitors. WO2011060295; 2011
135. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 2006; 12: 3233-7
136. Dunn KB, Heffler M, Golubovskaya VM. Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2010; 10: 722-34
137. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72
138. Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 2009; 11: 111-16
139. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010; 13: 1-14
140. Verastem, Inc. Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer. Available from: http://www.verastem.com/products/vs-6063.aspx
141. Golubovskaya VM, Virnig C, Cance WG. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2008; 47: 222-34
142. Walsh C, Tanjoni I, Uryu S, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010; 9: 778-90
143. Lipinski CA, Loftus JC. The Pyk2 FERM domain: a novel therapeutic Target. Expert Opin Ther Targets 2010; 14: 95-108
144. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005; 5: 505-15
145. Parsons JT, Slack-Davis J, Tilghman R, et al. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14: 627-32
146. Guessous F, Yang Y, Johnson E, et al. Cooperation between c-met and focal adhesion kinase family members in medulloblastoma and implications for therapy. Mol Cancer Ther 2012; 11: 288-97
147. Schultze A, Fiedler W. Therapeutic potential and limitations of new Fak inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 777-88
148. Golubovskaya VM, Ho B, Stright A, et al. Targeting Y397 FAK scaffolding compared with FAK kinase inhibition: Efficacy and specificity for tumor cells. Available from: http://meetinglibrary.asco.org/content/116818-132
149. Golubovskaya VM, Ho B, Zheng M, et al. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer 2013; 13: 342-55
150. Roberts WG, Ung E, Whalen P, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68: 1935-44
151. Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46: 488-96